利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.016 秒)

    METHODS FOR DETECTING MOLECULAR COMPLEXES
    2.
    发明申请
    METHODS FOR DETECTING MOLECULAR COMPLEXES 审中-公开

    公开(公告)号：WO2007147141A3

    公开(公告)日：2007-12-21

    申请号：PCT/US2007/071382

    申请日：2007-06-15

    申请人： VAN ANDEL RESEARCH INSTITUTE ,  HAAB, Brian, B.

    发明人： HAAB, Brian, B.

    IPC分类号： G01N33/53

    摘要： The invention includes methods for analyzing copies of an antibody microarray for a protein complexed with another molecule. In this method, one biological sample is divided and then incubated with copies of an antibody microarray. Each capture antibody is paired with a detection antibody, and only one detection antibody is incubated with each copy of the antibody microarray. The invention further includes methods to compare protein complexes under different conditions, methods of detecting an auto-immune response, and methods of detecting interaction between a protein and a small molecule.

    METHODS FOR DIAGNOSING THE MALIGNANT POTENTIAL OF PANCREATIC CYSTIC LESIONS
    8.
    发明申请
    METHODS FOR DIAGNOSING THE MALIGNANT POTENTIAL OF PANCREATIC CYSTIC LESIONS 审中-公开
    诊断胰腺炎淋巴细胞恶性潜能的方法

    公开(公告)号：WO2011082321A1

    公开(公告)日：2011-07-07

    申请号：PCT/US2010/062534

    申请日：2010-12-30

    申请人： VAN ANDEL RESEARCH INSTITUTE ,  THE REGENTS OF UNIVERSITY OF MICHIGAN ,  HAAB, Brian B. ,  SIMEONE, Diane

    发明人： HAAB, Brian B. ,  SIMEONE, Diane

    IPC分类号： C12Q1/00

    CPC分类号： G01N33/57438 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3092 ,  G01N33/6893 ,  G01N2333/42 ,  G01N2333/4724 ,  G01N2333/4725 ,  G01N2800/067 ,  G01N2800/50

    摘要： A method of diagnosing the malignant potential of a pancreatic cystic lesion in a subject including: detecting a glycan alteration in MUC5AC in a sample of pancreatic cystic lesion fluid from a subject, determining whether the glycan alteration is differentially present in the sample, and diagnosing the malignant potential of the pancreatic cystic lesion. A method of diagnosing the malignant potential of a pancreatic cystic lesion in a subject including: (a) detecting a glycan alteration in MUC5AC in a sample of pancreatic cystic lesion fluid from a subject, (b) detecting CA 19-9 in the sample, (c) determining whether the glycan alteration and CA 19-9 are differentially present in the sample, and (d) diagnosing the malignant potential of the pancreatic cystic lesion. Related methods of treatment and kits also are included.

    摘要翻译： 一种诊断受试者胰腺囊性病变的恶性潜力的方法，包括：检测来自受试者的胰腺囊性病变液样品中MUC5AC的聚糖改变，确定样品中是否差异存在聚糖改变，并诊断 胰腺囊性病变的恶性潜能。 一种诊断受试者胰腺囊性病变恶性潜力的方法，包括：（a）检测来自受试者的胰腺囊性病变液样品中MUC5AC的聚糖改变，（b）检测样品中的CA 19-9， （c）确定样品中聚糖改变和CA19-9是否差异存在，以及（d）诊断胰腺囊性病变的恶性潜能。 还包括相关治疗方法和试剂盒。

    LIGANDS FOR MINERALOCORTICOID RECEPTOR (MR) AND METHODS FOR SCREENING FOR OR DESIGNING MR LIGANDS
    10.
    发明申请
    LIGANDS FOR MINERALOCORTICOID RECEPTOR (MR) AND METHODS FOR SCREENING FOR OR DESIGNING MR LIGANDS 审中-公开
    矿物受体（MR）的配体和用于筛选或设计MR配体的方法

    公开(公告)号：WO2007059296A2

    公开(公告)日：2007-05-24

    申请号：PCT/US2006/044620

    申请日：2006-11-15

    申请人： VAN ANDEL RESEARCH INSTITUTE ,  XU, Huaqiang Eric ,  LI, Yong

    发明人： XU, Huaqiang Eric ,  LI, Yong

    IPC分类号： G01N33/567 ,  G06F19/00 ,  A61K31/573

    CPC分类号： G01N33/566

    摘要： The inventors disclose a 1.95Å crystal structure of the MR ligand binding domain containing a single C808S mutation bound to a corticosterone and the fourth LXXLL motif of steroid receptor coactivator-1 (SRC1-4). The inventors demonstrate that SRC1-4 is the most potent MR-binding motif and mutations that disrupt the MR/ SRC1-4 interactions abolish the ability of the full-length SRC1 to coactivate MR. The structure also reveals a compact steroid binding pocket with a unique topology that is primarily defined by key residues of helices 6 and 7. Also described are novel ligands for MR, methods for screening for and designing novel MR ligands, and methods for treating MR-related diseases.

    摘要翻译： 本发明人公开了含有与皮质酮结合的单一C808S突变和类固醇受体共激活因子-1（SRC1-4）的第四LXXLL基序的MR配体结合结构域的1.95Å晶体结构。 发明人证明SRC1-4是最有效的MR结合基序，并且破坏MR / SRC1-4相互作用的突变消除了全长SRC1共激活MR的能力。 该结构还揭示了具有唯一拓扑结构的紧凑型类固醇结合口袋，其主要由螺旋6和7的关键残基限定。还描述了MR的新配体，用于筛选和设计新型MR配体的方法，以及用于治疗MR- 相关疾病